Press release
Acute Bacterial Skin and Skin Structure Infections Market is expected to reach $11.4 billion by 2034
Acute Bacterial Skin and Skin Structure Infection
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71729
The ABSSSI market is driven by growing prevalence, rising hospital admissions, and innovation in novel antibiotics and combination therapies. However, the challenge of antimicrobial resistance (AMR) continues to pressure healthcare systems, spurring demand for next-generation drugs and stewardship programs.
Market Overview
• Market Size (2024): USD 6.8 billion
• Forecast (2034): USD 11.4 billion
• CAGR (2025-2034): 5.2%
Market growth is supported by strong antibiotic pipelines, global AMR initiatives, and rising awareness of hospital-acquired infections.
Key Highlights:
• MRSA remains the most common resistant pathogen in ABSSSI.
• Lipoglycopeptides, oxazolidinones, and new cephalosporins expanding treatment options.
• FDA and EMA approvals of novel antibiotics improving hospital protocols.
• Stewardship programs balancing innovation with responsible antibiotic use.
Segmentation Analysis
By Product Type:
• Antibiotics
o Lipoglycopeptides (Telavancin, Dalbavancin, Oritavancin)
o Oxazolidinones (Linezolid, Tedizolid)
o Tetracyclines (Doxycycline, Minocycline, Eravacycline)
o Cephalosporins (Ceftaroline)
o Carbapenems
• Combination Therapies
o Beta-lactam + Beta-lactamase inhibitors
• Supportive Care
o Wound care dressings
o Pain management drugs
By Platform:
• Small Molecule Antibiotics
• Biologics (emerging monoclonal antibodies)
• Supportive Care
By Technology:
• Antibiotic Discovery Platforms
• Rapid Diagnostic Technologies (PCR, MALDI-TOF)
• AI-Driven AMR Prediction Models
By End Use:
• Hospitals & ICUs
• Outpatient Clinics
• Specialty Infectious Disease Centers
• Home Healthcare (oral therapies)
By Application:
• Cellulitis
• Wound Infections
• Major Abscesses
• Post-Surgical Infections
Segmentation Summary:
Antibiotics dominate the market, but diagnostics and AI-based tools are gaining importance to reduce misuse and resistance. Hospitals remain the primary end users, while outpatient care is expanding for less severe cases.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71729/acute-bacterial-skin-and-skin-structure-infections-absssi-market
Regional Analysis
North America
• Largest market with ~41% share in 2024.
• High prevalence of MRSA driving strong antibiotic adoption.
• FDA approvals of novel therapies fueling growth.
Europe
• Holds ~29% share.
• Germany, UK, and France leading in stewardship programs.
• EMA approvals expanding access to new antibiotics.
Asia-Pacific
• Fastest-growing region with CAGR of ~6.4%.
• High burden of skin infections and rising AMR rates in India and China.
• Expanding hospital infrastructure and access to novel therapies.
Middle East & Africa
• Rising hospital-acquired infections but limited access to advanced antibiotics.
• Gradual improvements in tertiary care centers.
Latin America
• Brazil and Mexico leading regional growth.
• Growing antibiotic adoption and rising public health initiatives.
Regional Summary:
North America and Europe dominate today due to drug approvals and infrastructure, while Asia-Pacific is the fastest-growing market due to high disease burden and rapid healthcare expansion.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of ABSSSIs globally.
• Expanding approval of novel antibiotics targeting MRSA.
• Increasing hospital admissions and surgical procedures.
• Strong global focus on AMR solutions and stewardship programs.
Key Challenges:
• High levels of antibiotic resistance.
• Limited investment in antibiotic R&D due to low ROI.
• Strict stewardship regulations reducing overuse.
• Access disparities in low-income countries.
Latest Trends:
• Long-acting antibiotics (e.g., dalbavancin, oritavancin) reducing hospital stays.
• AI-driven platforms predicting AMR resistance patterns.
• Combination therapy development for multi-drug-resistant pathogens.
• Public-private partnerships (WHO, BARDA, CARB-X) supporting innovation.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71729
Competitor Analysis
Major Players in the Market:
• Pfizer Inc.
• Merck & Co., Inc. (Cubist legacy products)
• Novartis AG
• Allergan plc (AbbVie)
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics
• Basilea Pharmaceutica Ltd.
• Achaogen, Inc.
Competitive Summary:
Pfizer, Merck, and Novartis remain leaders with strong antibiotic portfolios. Companies like Paratek, Melinta, and Basilea are advancing novel therapies for resistant pathogens. Competition is focused on long-acting antibiotics, MRSA-specific therapies, and AMR stewardship compliance.
Conclusion
The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, valued at USD 6.8 billion in 2024, is projected to reach USD 11.4 billion by 2034, growing at a CAGR of 5.2%. Rising MRSA prevalence, expanding antibiotic innovation, and global AMR initiatives are driving market growth.
Key Takeaways:
• Antibiotics dominate but resistance challenges drive innovation.
• North America and Europe lead, while Asia-Pacific grows fastest.
• Long-acting antibiotics and AI-driven AMR solutions are emerging trends.
• Public-private partnerships are critical to advancing new therapies.
The next decade will redefine ABSSSI care through long-acting antibiotics, rapid diagnostics, and AI-driven resistance management, creating opportunities for pharma innovators, diagnostics firms, and healthcare providers worldwide.
This report is also available in the following languages : Japanese (急性細菌性皮膚・皮膚構造感染症(ABSSSI)市場), Korean (급성 세균성 피부 및 피부 구조 감염(ABSSSI) 시장), Chinese (急性细菌性皮肤和皮肤结构感染 (ABSSSI) 市场), French (Marché des infections bactériennes aiguës de la peau et des structures cutanées (ABSSSI)), German (Markt für akute bakterielle Haut- und Hautstrukturinfektionen (ABSSSI)), and Italian (Mercato delle infezioni batteriche acute della pelle e delle strutture cutanee (ABSSSI)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71729/acute-bacterial-skin-and-skin-structure-infections-absssi-market#request-a-sample
Our More Reports:
Neuropathic Ocular Pain (NOP)-Market
https://exactitudeconsultancy.com/reports/72288/neuropathic-ocular-pain-nop-market
Neurotrophic Keratopathy Market
https://exactitudeconsultancy.com/reports/72289/neurotrophic-keratopathy-market
Persistent Epithelial Defect Market
https://exactitudeconsultancy.com/reports/72290/persistent-epithelial-defect-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Bacterial Skin and Skin Structure Infections Market is expected to reach $11.4 billion by 2034 here
News-ID: 4177372 • Views: …
More Releases from Exactitude Consultancy
Onychomycosis Market is expected to reach USD 8.4 billion by 2034
Onychomycosis is a common fungal infection of the nails, caused primarily by dermatophytes, yeasts, and non-dermatophyte molds. It leads to nail discoloration, thickening, brittleness, and sometimes pain or secondary bacterial infections. Although not life-threatening, it significantly impacts quality of life and is associated with comorbidities like diabetes and peripheral vascular disease.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71727
The market for onychomycosis treatments is expanding due to rising prevalence,…
Human Immunodeficiency Virus Type 1 (HIV-1) Market is expected to reach USD 44.7 …
Human Immunodeficiency Virus Type 1 (HIV-1) remains a major global health challenge, responsible for the vast majority of HIV infections worldwide. While it is no longer the fatal disease it once was, thanks to antiretroviral therapy (ART), HIV-1 remains incurable and requires lifelong management. Patients benefit today from once-daily oral regimens, long-acting injectables, and pre-exposure prophylaxis (PrEP) to prevent transmission.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71725
The HIV-1…
Genital Herpes Market is expected to double, reaching USD 5.8 billion by 2034
Genital herpes is a chronic, sexually transmitted viral infection caused primarily by the herpes simplex virus type 2 (HSV-2), and in some cases by HSV-1. The condition is characterized by painful genital sores, recurrent outbreaks, and psychological distress. While not life-threatening, genital herpes remains a major public health issue due to its high global prevalence, risk of vertical transmission during childbirth, and role in increasing susceptibility to HIV.
Download Full PDF…
Catheter-Related Bloodstream Infection (CRBSI) Market is expected to reach USD 3 …
Catheter-related bloodstream infections (CRBSIs) are among the most serious and common hospital-acquired infections, caused when pathogens enter the bloodstream through central venous catheters (CVCs), peripherally inserted central catheters (PICCs), or other intravascular devices. These infections significantly increase patient morbidity, hospital stays, and healthcare costs, making their prevention and treatment a top priority in modern healthcare.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71721
The market for CRBSI is expanding due…
More Releases for ABSSSI
Revolutionizing Care: Breakthroughs Propel the ABSSSI Treatment Market into a Ne …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) represent a significant clinical and economic burden worldwide, affecting patients across outpatient clinics, hospitals, and long-term care facilities. From simple cellulitis to complex wound infections, these conditions require prompt, effective therapy to prevent serious complications and reduce healthcare costs. Today, the ABSSSI treatment market is undergoing a renaissance, driven by novel antibiotic classes, innovative delivery systems, and a heightened focus on antimicrobial…
ABSSSI Therapeutics Market Size in the 7MM is anticipated to increase by 2034 an …
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Bacterial Skin and Skin Structure Infections, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin Structure Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the ABSSSI Market! Download…
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Treatment Market Size …
Acute Bacterial Skin and Skin Structure Infections Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Acute Bacterial Skin and Skin Structure Infections Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market 2022-2028 | P …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Detailed …
Acute Bacterial Skin and Skin Structure Infections Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Acute Bacterial Skin and Skin Structure Infections depending on the industry's financial and non-financial impact. The complete range of information…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Rapidly Devel …
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based…
